Objective:

To report a case of acquired partial lipodystrophy developing after hematopoietic stem cell transplantation and to evaluate the therapeutic response to tirzepatide in this specific patient.

Approach:

Key Findings:

• The patient exhibited significant metabolic abnormalities associated with acquired partial lipodystrophy.
• Tirzepatide led to dramatic improvements in glycemic control, allowing for the discontinuation of insulin therapy.
• The HMW/total adiponectin ratio increased post-treatment, indicating potential improvement in adipocyte function.

Interpretation:

The case suggests that dual incretin receptor agonism may be an effective therapeutic strategy for managing severe insulin resistance linked to adipose tissue dysfunction.

Limitations:

• The findings are based on a single case study, limiting generalizability.
• Long-term effects and safety of tirzepatide in this context remain to be established.

Conclusion:

This case highlights the response to tirzepatide in treating metabolic disturbances associated with acquired partial lipodystrophy following HSCT.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.